dolutegravir lamivudine
Selected indexed studies
- Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection. (Drugs, 2020) [PMID:31865558]
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. (Lancet HIV, 2025) [PMID:40489982]
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. (Lancet, 2019) [PMID:30420123]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. (2017) pubmed
- An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV. (2022) pubmed
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. (2025) pubmed
- Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection. (2020) pubmed
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. (2019) pubmed
- Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection. (2019) pubmed
- Dolutegravir plus lamivudine for the treatment of HIV-1 infection. (2020) pubmed
- Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. (2022) pubmed
- Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial. (2025) pubmed
- Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial. (2022) pubmed